Cyclosporin pharmacokinetics in the elderly

Drugs and Aging

Volumn 15, Issue 3, 1999, Pages 197-205

  Kovarik, John M ^a   Ulrich Koelle, E ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; CYCLOSPORIN A; CYTOCHROME P450; ERYTHROMYCIN; GLYCOPROTEIN P; NIFEDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE;

AGED; AGING; ALLOGRAFT; AUTOIMMUNE DISEASE; BIOTRANSFORMATION; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG ELIMINATION; DRUG METABOLISM; DRUG TOLERABILITY; DRUG TRANSPORT; HUMAN; INTESTINE; INTESTINE EPITHELIUM; INTRAVENOUS DRUG ADMINISTRATION; LIVER; META ANALYSIS; NEPHROTOXICITY; ORAL DRUG ADMINISTRATION; ORGAN TRANSPLANTATION; PARESTHESIA; POLYPHARMACY; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RISK; SIDE EFFECT;

AGED; CLINICAL TRIALS; COMORBIDITY; CYCLOSPORINE; DRUG INTERACTIONS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER; PHARMACOGENETICS;

EID: 0032837161     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199915030-00003     Document Type: Review

References (38)

1. Fahr A. Cyclosporin clinical pharmacokinetics. Clin Pharmacokinet 1993; 24: 472-95
2. Wells G, Tugwell P. International consensus report: the use of cyclosporin A in rheumatoid arthritis. Br J Rheumatol 1993; 32: 1-3
3. Nesher G, Moore TL. Rheumatoid arthritis in the aged: incidence and optimal management. Drugs Aging 1998; 3: 487-501
4. Kaipiainen-Seppanen O, Abo K, Isomaki H, et al. Shift in the incidence of rheumatoid arthritis toward elderly patients in Finland. Clin Exp Rheumatol 1996; 14: 537-42
5. Kinirons MT, Crome P. Clinical pharmacokinetic considerations in the elderly. Clin Pharmacokinet 1997; 33: 302-31
6. Dawling S, Crome P. Clinical pharmacokinetics in the elderly: an update. Clin Pharmacokinet 1989; 17: 236-63
7. Kaminsky LS, Fasco MJ. Small intestine cytochrome P450. Crit Rev Toxicol 1992; 21: 407-22
8. Wu CY, Benet LZ, Hebert MF, et al. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin Pharmacol Ther 1995; 58: 492-7
9. Kolars JC, Awni WM, Merion RM, et al. First-pass metabolism of cyclosporin by the gut. Lancet 1991; 338: 1488-90
10. Webber IR, Peters WHM, Back DJ. Cyclosporin metabolism by human gastrointestinal mucosal microsomes. Br J Clin Pharmacol 1992; 33: 661-4
11. Woodhouse KM, James OFW. Hepatic drug metabolism and ageing. Br Med Bull 1990; 46: 22-35
12. Hunt CM, Westerkam WR, Stave GM. Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol 1992; 44: 275-83
13. Miglioli PA, Pivetta P, Strazzabosco M, et al. Effect of age on single and multiple dose pharmacokinetics of crythromycin. Eur J Clin Pharmacol 1990; 39: 164-4
14. Robertson DRC, Waller DG, Renwick AG, et al. Age related changes in the pharmacokinetics and pharmacodynamics of nifedipine. Br J Clin Pharmacol 1988; 25: 297-305
15. Thiebaut F, Tsuruo T, Harmada H, et al. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A 1987; 84; 7735-8
16. Sacki T, Ueda K, Tanigawara Y, et al. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 1993; 268: 6077-80
17. Lown KS, Mayo RR, Leichtman AB, et al. Role of intestinal P-glycoprotein (mdrl) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 1997; 62: 248-60
18. Gupta S. P-glycoprotein expression and regulation: age-related changes and potential effects on drug therapy. Drugs Aging 1995; 7: 420-37
19. Denham MJ. Adverse drug reactions. Br Med Bull 1990; 46: 53-62
20. Lake KD. Management of drug interactions with cyclosporine. Pharmacotherapy 1991; 11: 110S-8
21. Bjerrum L, Sogarrd J, Hallas J, et al. Polypharmacy: correlations with sex, age and drug regimen. Eur J Clin Pharmacol 1998; 54: 197-202
22. Lampen A, Christians L, Bader A, et al. Drug interactions and interindividual variability of ciclosporin metabolism in the small intestine. Pharmacology 1996; 52: 159-68
23. Pichard L., Fabre I, Fabre G. et al. Cyclosporin A drug interactions: screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab Dispos 1990; 18: 595-606
24. Ball PE, Munzer H, Keller HP, et al. Specific 3H radioimmunoassay with a monoclonal antibody for monitoring cyclosporine in blood. Clin Chem 1988; 34: 257-60
25. Revmond JP, Steimer JL, Nicderberger W. On the dose dependency of cyclosporin A absorption and disposition in healthy volunteers. J Pharmacokinet Biopharm 1989; 16: 331-53
26. Food and Drug Administration Center for Drug Evaluation. Guidance: statistical procedures for bioequivalence studies. Rockville (MD): Food and Drug Administration Center for Drug Evaluation, 1992
27. Schuirmann DJ. A comparison of the two one-sided procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987; 15: 657-80
28. Kahan BD, Kramer WG, Wideman C. Demographic factors affecting the pharmacokinetics of cyclosporine estimated by radioimmunoassay. Transplantation 1986; 41: 459-67
29. Kyhl I.F.B, Rasmussen SN, Aaron L, et al. Population pharmacokinetics of cyclosporine: influence of covariables and assessment of cyclosporine absorption in kidney, lung, heart, and heart-lung transplanted patients [abstract]. Transplant Proc 1998; 30: 1680
30. Torley H, Yocum D. Effects of dose and treatment duration on adverse experience with cyclosporine in RA: analysis of North American trials [abstract]. Arthritis Rheum 1994; 37: Suppl.: 334
31. Gardner G, Furst DE. Disease-modifying antirheumatic drugs: potential effects in older patients. Drugs Aging 1995; 7:420-37
32. Santiago-Delphin EA. Transplantation in the elderly: changing philosophy. Transplant Proc 1996; 28: 3408-9
33. Mallick NP, Dyer P, Johnson RW. Transplantation in the elderly. Nephrol Dial Transplant 1996; 11 Suppl. 9: 95-7
34. Cantarovich D, Baatard R, Baranger T, et al. Cadaveric renal transplantation after 60 years of age: a single center experience. Transplant Int 1994; 7: 33-8
35. Pirsch JD, Stratta RJ, Armbrust MJ, et al. Cadaveric renal transplantation with cyclosporine in patients more than 60 years of age. Transplantation 1989; 47: 259-61
36. Vivas CA, Hickey DP, Jordan ML, et al. Renal transplantation in patients 65 years old or older. J Urol 1992; 147: 990-3
37. Smits JM, DeMeester J, Persijn GG, et al. Long-term results of solid organ transplantation: report from the Eurotransplant International Foundation. Clin Transplant 1996; 10: 109-27
38. Anderson IF, Helve T, Hannonen P, et al. Conversion of patients with rheumatoid arthritis from the conventional to a microemulsion formulation of cyclosporin: a double blind comparison to screen for differences in safety, efficacy, and pharmacokinetics. J Rheumatol 1999; 26; 556-62